Literature DB >> 11986610

Role of CD8+ lymphocytes in chronic rejection of transplanted hearts.

Michael P Fischbein1, James Yun, Hillel Laks, Yoshihito Irie, Michael C Fishbein, Benjamin Bonavida, Abbas Ardehali.   

Abstract

BACKGROUND: The contribution of CD8(+) lymphocytes to the pathogenesis of cardiac allograft vasculopathy, or chronic rejection in heart transplants, remains undefined. We used both major histocompatibility complex class I mismatched and major histocompatibility complex class II mismatched models of cardiac allograft vasculopathy to characterize the role of CD8(+) lymphocytes in the development of cardiac allograft vasculopathy.
METHODS: Donor hearts from B10.A mice were transplanted into B10.BR recipients (major histocompatibility complex class I mismatched). Donor hearts were harvested at 1, 7, 14, and 30 days after transplantation and (1) quantitated morphometrically for lesion development, (2) stained immunohistochemically, or (3) digested for isolation of graft-infiltrating cells. The cytotoxic phenotype of graft-infiltrating CD8(+) lymphocytes was determined with flow cytometry. Intracellular cytokine staining of CD8(+) and CD4(+) lymphocytes for interleukin 2, interferon g, interleukin 4, and interleukin 10 was performed with 2-color flow cytometry. Finally, B6.C-H2(bm12) donor hearts were transplanted into either C57BL/6 wild-type (major histocompatibility complex class II mismatched) or CD8 -/- knockout recipients and examined for the development of cardiac allograft vasculopathy.
RESULTS: In the major histocompatibility complex class I mismatched model, CD8(+) lymphocytes were the predominant T-lymphocyte subset that infiltrated the allografts and demonstrated markers of activation. The intracellular cytokine-staining assay demonstrated that CD8(+) lymphocytes were the primary sources of allograft interleukin 2 and interferon gamma. Intimal lesions developed in the allografts by day 14 (12.0% +/- 4.0%) and further increased by day 30 (44.0% +/- 5.0%). In the major histocompatibility complex class II mismatched model, the donor hearts in the CD8 -/- knockout recipients had substantially less severe intimal lesions when compared with the donor hearts in wild-type recipients (19.0% +/- 6.0% vs 50.0% +/- 7.0%, respectively; P <.05).
CONCLUSIONS: In both major histocompatibility complex class I and II mismatched models, CD8(+) lymphocytes contribute significantly to chronic rejection. The findings of this study suggest that control of chronic rejection requires interventions directed at CD8(+) lymphocytes.

Entities:  

Mesh:

Year:  2002        PMID: 11986610     DOI: 10.1067/mtc.2002.120008

Source DB:  PubMed          Journal:  J Thorac Cardiovasc Surg        ISSN: 0022-5223            Impact factor:   5.209


  8 in total

1.  Crystallization and preliminary X-ray structural studies of a high-affinity CD8alphaalpha co-receptor to pMHC.

Authors:  David K Cole; Pierre J Rizkallah; Malkit Sami; Nikolai M Lissin; Feng Gao; John I Bell; Jonathan M Boulter; Meir Glick; Anne Lise Vuidepot; Bent K Jakobsen; George F Gao
Journal:  Acta Crystallogr Sect F Struct Biol Cryst Commun       Date:  2005-02-12

2.  Blockade of Notch ligand δ1 promotes allograft survival by inhibiting alloreactive Th1 cells and cytotoxic T cell generation.

Authors:  Leonardo V Riella; Takuya Ueno; Ibrahim Batal; Sacha A De Serres; Ribal Bassil; Wassim Elyaman; Hideo Yagita; José O Medina-Pestana; Anil Chandraker; Nader Najafian
Journal:  J Immunol       Date:  2011-09-26       Impact factor: 5.422

3.  The role of MIG/CXCL9 in cardiac allograft vasculopathy.

Authors:  James J Yun; Michael P Fischbein; David Whiting; Yoshihito Irie; Michael C Fishbein; Marie D Burdick; John Belperio; Robert M Strieter; Hillel Laks; Judith A Berliner; Abbas Ardehali
Journal:  Am J Pathol       Date:  2002-10       Impact factor: 4.307

4.  Perforin mediates endothelial cell death and resultant transplant vascular disease in cardiac allografts.

Authors:  Jonathan C Choy; Alexandra Kerjner; Brian W Wong; Bruce M McManus; David J Granville
Journal:  Am J Pathol       Date:  2004-07       Impact factor: 4.307

5.  Optimizing PLG nanoparticle-peptide delivery platforms for transplantation tolerance using an allogeneic skin transplant model.

Authors:  Sahil Shah; Saeed Daneshmandi; Kevin R Hughes; Shuangjin Yu; Angela M Bedoya; Lonnie D Shea; Xunrong Luo
Journal:  Biomaterials       Date:  2019-05-01       Impact factor: 12.479

6.  A novel role of CD4 Th17 cells in mediating cardiac allograft rejection and vasculopathy.

Authors:  Xueli Yuan; Jesus Paez-Cortez; Isabela Schmitt-Knosalla; Francesca D'Addio; Bechara Mfarrej; Michela Donnarumma; Antje Habicht; Michael R Clarkson; John Iacomini; Laurie H Glimcher; Mohamed H Sayegh; M Javeed Ansari
Journal:  J Exp Med       Date:  2008-12-01       Impact factor: 14.307

Review 7.  Emerging Concepts of Tissue-resident Memory T Cells in Transplantation.

Authors:  Jianing Fu; Megan Sykes
Journal:  Transplantation       Date:  2022-11-24       Impact factor: 5.385

8.  miR-21 antagonism reprograms macrophage metabolism and abrogates chronic allograft vasculopathy.

Authors:  Vera Usuelli; Moufida Ben Nasr; Francesca D'Addio; Kaifeng Liu; Andrea Vergani; Basset El Essawy; Jun Yang; Emma Assi; Mayuko Uehara; Chiara Rossi; Anna Solini; Annalisa Capobianco; Elena Rigamonti; Luciano Potena; Massimo Venturini; Mario Sabatino; Lorena Bottarelli; Enrico Ammirati; Maria Frigerio; Eduardo Castillo-Leon; Anna Maestroni; Cinzia Azzoni; Cristian Loretelli; Andy Joe Seelam; Albert K Tai; Ida Pastore; Gabriella Becchi; Domenico Corradi; Gary A Visner; Gian V Zuccotti; Nelson B Chau; Reza Abdi; Marcus G Pezzolesi; Paolo Fiorina
Journal:  Am J Transplant       Date:  2021-05-03       Impact factor: 9.369

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.